CA
SLRN

Clearstead Advisors’s ACELYRIN SLRN Stock Holding History

Clearstead Advisors’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-114
Closed -$563 – 2181
2024
Q3 		$563 Hold
114
– – ﹤0.01% 1948
2024
Q2 		$503 Buy
+114
New +$534 ﹤0.01% 1935

Other funds holding SLRN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Clearstead Advisors's SLRN Position: Q4 2024 in Review

Clearstead Advisors sold out of ACELYRIN (SLRN) in Q4 2024, closing a stake of 114 shares — an estimated $563 sold.

Clearstead Advisors first reported a position in SLRN in Q2 2024 and held it in 2 quarters. The position peaked at $563 in Q3 2024. 125 funds tracked by Wall St. Rank hold SLRN as of Q4 2024.

  • Clearstead Advisors reported no remaining ACELYRIN position as of Q4 2024 after selling out during the quarter.
  • Clearstead Advisors sold 114 ACELYRIN shares in Q4 2024, an estimated $563.
  • Clearstead Advisors first reported a position in ACELYRIN in Q2 2024 and held it in 2 quarters.
  • Clearstead Advisors's ACELYRIN position peaked at $563 in Q3 2024.
  • 125 funds tracked by Wall St. Rank held ACELYRIN as of Q4 2024.

Based on Clearstead Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.